PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer
- 1 January 2005
- journal article
- Published by Elsevier in Cancer Detection Prevention
- Vol. 29 (2), 170-174
- https://doi.org/10.1016/j.cdp.2004.07.006
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancerCancer Cell, 2003
- In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicinGene Therapy, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Role of PI3K Signaling in Survival and Progression of LNCaP Prostate Cancer Cells to the Androgen Refractory StateEndocrinology, 2001
- PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 ExpressionJournal of Biological Chemistry, 2001
- Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancerOncogene, 2001
- Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced ApoptosisPublished by Elsevier ,2001
- MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cellsOncogene, 2000
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate CancerScience, 1997